science

Tissue-agnostic cancer drug

Tissue-agnostic cancer drug is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Tissue-agnostic cancer drug rather than just read about it. In short: Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear. Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab, Larotrectinib, Selpercatinib, Entrectinib, and Pralsetinib.

Key takeaways

Tissue-agnostic cancer drug belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Tissue-agnostic cancer drug to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Tissue-agnostic cancer drug from memory before moving on to harder problems.

Reference excerpt

Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear. Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab, Larotrectinib, Selpercatinib, Entrectinib, and Pralsetinib.

History Pembrolizumab was approved by the US Food and Drug Administration in May 2017. Larotrectinib was approved by the FDA in November, 2018. Selpercatinib (LOXO-292) received priority review in September 2018 and was approved for medical use in the United States in May 2020. Entrectinib was approved for medical use in the United States in August 2019, in Australia in May 2020, and in the European Union in July 2020. Pralsetinib was approved for medical use in the United States in September 2020. Dabrafenib and trametinib have been approved as tissue-agnostic drugs for solid tumors that are B-RAF positive. Tissue-agnostic cancer drugs that are under development as of May 2022 include Selitrectinib (Loxo-195) and anti-ERBB3 antibodies.

References

Worked examples

Example 1 — a first encounter with Tissue-agnostic cancer drug

Start with the simplest possible case. Write down what Tissue-agnostic cancer drug claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tissue-agnostic cancer drug before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tissue-agnostic cancer drug ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tissue-agnostic cancer drug

In research: Tissue-agnostic cancer drug appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Tissue-agnostic cancer drug in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Tissue-agnostic cancer drug is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antineoplastic and immunomodulating drug stubs, Tissue agnostic antineoplastic agents, so understanding it makes those chapters shorter.
In everyday life: Look for Tissue-agnostic cancer drug outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Tissue-agnostic cancer drug” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Tissue-agnostic cancer drug in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Tissue-agnostic cancer drug means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Tissue-agnostic cancer drug out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tissue-agnostic cancer drug in simple terms?

Why does Tissue-agnostic cancer drug matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tissue-agnostic cancer drug?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tissue-agnostic cancer drug.